Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development.
Pediatric drug development faces many difficulties. Traditionally, pediatric drug doses are simply calculated linearly based on the body weight, age, and body surface area of adults. Due to the ontogeny of children, this simple linear scaling may lead to drug overdose in pediatric patients. The physiologically based pharmacokinetic (PBPK) model, as a mathematical model, contributes to the research and development of pediatric drugs. An example of a PBPK model guiding drug dose selection in pediatrics has emerged and has been approved by the relevant regulatory agencies. In this review, we discuss the principle of the PBPK model, emphasize the necessity of establishing a pediatric PBPK model, introduce the absorption, distribution, metabolism, and excretion of the pediatric PBPK model, and understand the various applications and related prospects of the pediatric PBPK model.
['Wang|Kefei|K|https://orcid.org/0000-0002-3893-3557', 'Jiang|Kun|K|', 'Wei|Xiaoyi|X|', 'Li|Yulan|Y|', 'Wang|Tiejie|T|', 'Song|Yang|Y|']
D000328:Adult D002648:Child D003198:Computer Simulation D000076722:Drug Development D006801:Humans D008954:Models, Biological D010372:Pediatrics D010599:Pharmacokinetics D012107:Research Design
pediatrics drug development PBPK model